Skip to main content
SHANGHAI SERUM BIO-TECHNOLOGY CO., LTD. logo

SHANGHAI SERUM BIO-TECHNOLOGY CO., LTD. — Investor Relations & Filings

Ticker · 688163 ISIN · CNE1000059X8 LEI · 8368001TREMN2G5DDS70 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 335 across all filing types
Latest filing 2023-12-01 Governance Information
Country CN China
Listing Shanghai Stock Exchange 688163

About SHANGHAI SERUM BIO-TECHNOLOGY CO., LTD.

https://www.serum-china.com.cn/en/

Shanghai Serum Bio-Technology Co., Ltd. is a specialized biopharmaceutical enterprise focused on the research, development, and manufacturing of therapeutic biological products. The company primarily produces a range of antiserums and antitoxins, including specialized antivenoms for various snake species, tetanus antitoxins, and rabies immunoglobulins. Its product portfolio supports emergency medical care and infectious disease management. The organization maintains advanced production facilities compliant with Good Manufacturing Practice (GMP) standards to ensure the safety and efficacy of its biological treatments. By leveraging biotechnological innovation, the company serves clinical needs in healthcare sectors, providing critical life-saving interventions for envenomation and acute bacterial toxins.

Recent filings

Filing Released Lang Actions
独立董事提名人声明与承诺（傅以尚）
Governance Information Classification · 95% confidence The document is a formal statement from the board of Shanghai Sairen Biotechnology Co., Ltd. nominating an independent director candidate. It details the qualifications, independence criteria, and compliance with relevant laws and regulations for the nominee. There is no financial data, no report of financial performance, no voting results, no management changes announcement, and no mention of any report publication or regulatory filing. The document is a nomination statement related to board composition but does not announce a change or appointment, nor is it a proxy solicitation or voting result. It is a governance-related document focused on director nomination and compliance with governance rules. Therefore, the best fitting category is Governance Information (CGR). The document length is short and focused on governance compliance, not a full report or announcement of a meeting or vote.
2023-12-01 Chinese
赛伦生物：关于召开2023年第三季度业绩说明会的公告
Investor Presentation Classification · 95% confidence The document is an announcement about the scheduling and details of a 2023 third quarter earnings explanation meeting (业绩说明会) to be held on November 22, 2023. It references the previously released 2023 third quarter report but does not contain actual financial data or detailed financial statements itself. The document is short (1540 characters) and primarily provides logistical information about the upcoming investor call and how investors can participate and ask questions. This fits the profile of an Investor Presentation (IP) or Earnings Release (ER) event announcement. However, since it is specifically about an earnings explanation meeting (业绩说明会) rather than the initial earnings release, and it includes details about the meeting format and participation, the best classification is Investor Presentation (IP).
2023-11-14 Chinese
赛伦生物：关于公司实际控制人之一、董事长解除留置的公告
Board/Management Information Classification · 95% confidence The document is an announcement regarding the lifting of a detention order on the company's actual controller and chairman. It details changes in the chairman's status and the resumption of his duties. There is no financial data, no report attached or referenced as being published, and no mention of financial results or regulatory certifications. The content relates to management status and control information, specifically about the chairman's legal and operational status. This fits best under Board/Management Information (MANG), which covers announcements of changes in the company's board or senior management.
2023-10-29 Chinese
赛伦生物：2023年第三季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "2023 年第三季度报告" which translates to "2023 Third Quarter Report." It contains detailed financial data including balance sheets, profit and loss statements, cash flow statements, and notes on financial performance for the third quarter of 2023. The document is approximately 15,000 characters long, indicating it is a full report rather than a brief announcement. The content includes unaudited quarterly financial statements and management assurances about the accuracy of the report. This matches the definition of an Interim / Quarterly Report (IR), which is a comprehensive financial report for a period shorter than a full fiscal year containing actual financial statements and substantive financial data and analysis. There is no indication that this is an announcement of a report or a certification letter, so it is not classified as RPA or RNS. Therefore, the document is best classified as an Interim / Quarterly Report (IR). 9M 2023
2023-10-27 Chinese
赛伦生物：关于独立董事任期届满暨延期选举独立董事的公告
Board/Management Information Classification · 100% confidence The document is an announcement from Shanghai SAILUN Biotech Co., Ltd. regarding the expiration of the term of independent directors and the postponement of the election of new independent directors. It discusses board composition and compliance with regulations on independent directors. There is no financial data, no mention of annual or quarterly reports, no audit information, no voting results, and no other financial or legal proceedings content. The document is about board/management information, specifically about changes and continuity in the board of directors. Therefore, the appropriate classification is Board/Management Information (MANG). The document length is short and focused on management changes, not a report or announcement of a report publication.
2023-09-20 Chinese
方正证券承销保荐有限责任公司关于上海赛伦生物技术股份有限公司2023年半年度持续督导跟踪报告
Interim / Quarterly Report Classification · 95% confidence The document is titled as a '2023年半年度持续督导跟踪报告' which translates to '2023 Semi-Annual Continuous Supervision Follow-up Report'. It is issued by the underwriting and sponsoring institution (方正证券承销保荐有限责任公司) for Shanghai Sailun Biotechnology Co., Ltd. The content includes detailed descriptions of continuous supervision work, risk factors, financial data for the first half of 2023, R&D progress, use of raised funds, and shareholding information. The document contains substantive financial data and analysis for the half-year period ending June 30, 2023, including income, profit, cash flow, and asset changes. It also discusses compliance with regulatory requirements and risk disclosures. This matches the characteristics of an Interim / Quarterly Report (IR), which is a comprehensive financial report for a period shorter than a full fiscal year with actual financial statements and substantive analysis. The document is about 15,000 characters, indicating it is a full report rather than a brief announcement or certification. Therefore, the correct classification is Interim / Quarterly Report (IR). H1 2023
2023-09-15 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.